191 related articles for article (PubMed ID: 37456895)
1. A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms.
Qi G; Liu J; Tao S; Fan W; Zheng H; Wang M; Yang H; Liu Y; Liu H; Zhou F
PeerJ; 2023; 11():e15675. PubMed ID: 37456895
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis.
Kaymaz E; Ozer E; Unverdi H; Hucumenoglu S
Indian J Pathol Microbiol; 2017; 60(4):510-514. PubMed ID: 29323063
[TBL] [Abstract][Full Text] [Related]
3. MOLECULAR CHARACTERISTICS OF THE HETEROGENEITY OF NON-INVASIVE PAPILLARY UROTHELIAL CARCINOMAS AND THE MARKERS OF THEIR RECURRENCE.
Kajaia D; Kochiashvili D; Muzashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2021; (316-317):178-184. PubMed ID: 34511468
[TBL] [Abstract][Full Text] [Related]
4. Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT: Comparative Analyses with Noninvasive Low-Grade Papillary Urothelial Carcinoma (LGPUC).
Kim JK; Moon KC; Jeong CW; Kwak C; Kim HH; Ku JH
J Cancer; 2017; 8(15):2885-2891. PubMed ID: 28928878
[No Abstract] [Full Text] [Related]
5. Cytologic diagnosis of low-grade papillary urothelial neoplasms (low malignant potential and low-grade carcinoma) in the context of the 1998 WHO/ISUP classification.
Whisnant RE; Bastacky SI; Ohori NP
Diagn Cytopathol; 2003 Apr; 28(4):186-90. PubMed ID: 12672093
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic study of 60 cases of urothelial neoplasms with inverted growth patterns: Reclassification by international consultation on urologic disease (ICUD) recommendations.
Bang H; Park H; Park S; Choi E; Cho MS; Sung SH; Choi SY; Cho YM; Jeong SU; Ro JY
Ann Diagn Pathol; 2020 Feb; 44():151433. PubMed ID: 31785538
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological analysis of recurrence and progression of low-grade papillary urothelial carcinoma of the urinary bladder: Predicting the outcome.
Bahmad HF; Lopez O; Moreno JCA; Lopez K; Malik F; Salami A; Nieder AM; Omarzai Y; Poppiti RJ
Ann Diagn Pathol; 2022 Dec; 61():152030. PubMed ID: 36055007
[TBL] [Abstract][Full Text] [Related]
8. Expression of MUC1 (Ma695) in noninvasive papillary urothelial neoplasm according to the 2004 World Health Organization classification of the noninvasive urothelial neoplasm. An immunologic tool for the pathologist?
Garbar C; Mascaux C
Anal Quant Cytol Histol; 2011 Oct; 33(5):277-82. PubMed ID: 22611755
[TBL] [Abstract][Full Text] [Related]
9. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
[TBL] [Abstract][Full Text] [Related]
10. Investigation of Ki67 and Phospho-Histone H3 Expressions in Urothelial Carcinoma of the Bladder by Immunohistochemical Method.
Yüceer RO; Başpınar Ş
Cureus; 2024 Feb; 16(2):e55297. PubMed ID: 38558732
[TBL] [Abstract][Full Text] [Related]
11. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
[TBL] [Abstract][Full Text] [Related]
13. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma.
Rodríguez-Alonso A; Pita-Fernández S; González-Carreró J; Nogueira-March JL
Eur Urol; 2002 Feb; 41(2):182-8; discussion 188-9. PubMed ID: 12074407
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.
Culpan M; Turan T; Ozkanli SS; Zenginkinet T; Kazan O; Ucar T; Atis G; Caskurlu T; Yildirim A
J Cancer Res Ther; 2021; 17(2):434-442. PubMed ID: 34121689
[TBL] [Abstract][Full Text] [Related]
15. The Association of A Number of Predictive Factors for The Recurrence of Papillary Urothelial Neoplasm of Low Malignant Potential: Prognostic Analysis From Multiple Academic Centers.
Kim KH; Lee SH; Kim SI; Chung BH; Koo KC; Cho JS; Bang WJ; Park JY; Hong SJ
Urol J; 2019 Dec; 16(6):558-562. PubMed ID: 30882164
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer.
Jones TD; Cheng L
Urol Oncol; 2021 May; 39(5):286-290. PubMed ID: 35550107
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of atypical papillary urothelial hyperplasia.
Swierczynski SL; Epstein JI
Hum Pathol; 2002 May; 33(5):512-7. PubMed ID: 12094376
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
[TBL] [Abstract][Full Text] [Related]
19. [Urothelial hyperplastic lesion with endophytic growth pattern: a clinicopathologic study].
Xiao L; Wang CF; Zhu XZ; Yin YL; Chen Y; Lu C; Yu B
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):319-23. PubMed ID: 21756826
[TBL] [Abstract][Full Text] [Related]
20. Superficial papillary urothelial neoplasms of the bladder (PTA E PT1): correlation of expression of P53, KI-67 and CK20 with histologic grade, recurrence and tumor progression.
Ogata DC; Marcondes CA; Tuon FF; Busato WF; Cavalli G; Czeczko LE
Rev Col Bras Cir; 2012; 39(5):394-400. PubMed ID: 23174791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]